- Home
- PBT vs CRGX Comparison
PBT vs CRGX Comparison
Compare PBT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- CRGX
- Stock Information
- Founded
- PBT 1980
- CRGX 2021
- Country
- PBT United States
- CRGX United States
- Employees
- PBT N/A
- CRGX N/A
- Industry
- PBT Oil & Gas Production
- CRGX
- Sector
- PBT Energy
- CRGX
- Exchange
- PBT Nasdaq
- CRGX Nasdaq
- Market Cap
- PBT 562.6M
- CRGX 190.0M
- IPO Year
- PBT N/A
- CRGX 2023
- Fundamental
- Price
- PBT $12.94
- CRGX $4.59
- Analyst Decision
- PBT
- CRGX Hold
- Analyst Count
- PBT 0
- CRGX 7
- Target Price
- PBT N/A
- CRGX $5.33
- AVG Volume (30 Days)
- PBT 151.7K
- CRGX 1.9M
- Earning Date
- PBT 01-01-0001
- CRGX 08-11-2025
- Dividend Yield
- PBT 4.21%
- CRGX N/A
- EPS Growth
- PBT N/A
- CRGX N/A
- EPS
- PBT 0.48
- CRGX N/A
- Revenue
- PBT $24,140,674.00
- CRGX N/A
- Revenue This Year
- PBT N/A
- CRGX $57.81
- Revenue Next Year
- PBT N/A
- CRGX N/A
- P/E Ratio
- PBT $26.51
- CRGX N/A
- Revenue Growth
- PBT N/A
- CRGX N/A
- 52 Week Low
- PBT $8.01
- CRGX $3.00
- 52 Week High
- PBT $14.26
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- PBT 65.87
- CRGX 61.56
- Support Level
- PBT $12.66
- CRGX $4.32
- Resistance Level
- PBT $13.73
- CRGX $4.63
- Average True Range (ATR)
- PBT 0.38
- CRGX 0.16
- MACD
- PBT 0.00
- CRGX 0.04
- Stochastic Oscillator
- PBT 59.49
- CRGX 76.44
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.